Improvement in Quality of Life and Non‐Motor Symptoms Associated With
OFF
Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa
Diego Santos García, María Cerdán Sánchez, Rosa Yáñez Baña, Iria Cabo, Maria Icíar Cimas Hernando ABSTRACT
Background
CVT‐301 (Inbrija) has demonstrated its effectiveness in treating OFF periods in people with Parkinson's disease (PwP). However, its effect on non‐motor symptoms (NMS) and quality of life has not been researched yet. Our aim was to analyze the change observed in health‐related quality of life (HRQoL) and, as a secondary exploratory analysis, NMS associated with OFF episodes in PwP treated with CVT‐301.
Methods
INLEVO‐LIFE PD (an open‐label study of the effect of INhaled LEVOdopa on quality of LIFE and non‐motor symptoms in Parkinson's Disease) is a prospective open‐label study conducted in five centers in Spain. The change from baseline (V0) to the end of the observational period (12 ± 2 weeks) (V12w) in the 39‐item Parkinson's Disease Quality of Life Questionnaire (PDQ‐39) total score was the primary efficacy measure.
Results
Forty PD patients (age 62.3 ± 9.2 years; 55% males) were included between March/2024 and November/2025. At 12 weeks, 34 patients were using CVT‐301 and completed the follow‐up (85%). The PDQ39 total score decreased from 43.6 ± 24.2 at V0 to 31.4 ± 20.6 at V12w ( p < 0.0001). A significant decrease was observed in the mean score of 4 domains of the PDQ39. NMS burden was reduced at v12w from the OFF state to 30, 60, and 90 min after using CVT‐301 ( p < 0.0001). Mean daily OFF time decreased by 1.6 ± 1.9 h ( p < 0.0001). Adverse events related to CVT‐301 were reported in 35% of the patients.
Conclusion
HRQoL and NMS associated with OFF episodes improved in PwP after 12 weeks using CVT‐301.